WCN Express: Extended-Release Calcifediol Slows Chronic Kidney Disease Progression
Reported at the World Congress of Nephrology (WCN 2026) in Yokohama, a post-hoc analysis of a Chinese phase 3 bridging study showed that among patients with secondary hyperparathyroidism (SHPT) receiving extended-release calcifediol (ERC), those whose intact parathyroid hormone (iPTH) fell by >=30% from baseline had a significantly slower decline in eGFR than non-responders (-2.4 +/- 3.8 vs -5.1 +/- 5.3 mL/min/1.73 m2, p=0.036), with no effect of sustained iPTH reduction on safety parameters - consistent with findings from US studies.
See what happened ↗


